Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event

Noah M. Hahn, Constantin Yiannoutsos, Kristina Kirkpatrick, Jaya Sharma, Christopher J. Sweeney

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background Elevated markers of bone turnover are prognostic for shorter survival in castration-resistant prostate cancer. We aimed to determine the prognostic value of bone turnover markers in metastatic hormone-sensitive prostate cancer. Patients and Methods Markers of bone turnover (urine deoxypyridinoline [DPD] and N-telopeptide, serum bone alkaline phosphatase (AP), and osteocalcin [OC]) from baseline and after 6 months of study were assessed in men enrolled in a prospective metastatic prostate cancer trial with androgen deprivation therapy (ADT) with or without risedronate (ClinicalTrials.gov, NCT00216060). Results Serum samples were collected from 63 patients with bone involvement and a median follow-up of 39.7 months. A multivariate model using Cox regression - which included prostate-specific antigen (PSA) nadir, bisphosphonate treatment, and extent of metastases - showed that suppression of bone turnover markers after 6 months of therapy compared with baseline was significantly associated with longer skeletal-related event (SRE)-free survival. ADT without bisphosphonate therapy was also associated with a decline in markers of bone turnover, presumably resulting from direct anticancer activity. Elevated baseline bone turnover markers were not prognostic. Conclusion Failure to suppress bone turnover while receiving ADT, even when otherwise responding to therapy, may identify patients with hormone-sensitive metastatic prostate cancer who are destined for a shorter time to SREs and progression.

Original languageEnglish
JournalClinical Genitourinary Cancer
Volume12
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Bone Remodeling
Prostatic Neoplasms
Hormones
Androgens
Diphosphonates
Therapeutics
Bone and Bones
Castration
Osteocalcin
Prostate-Specific Antigen
Serum
Proportional Hazards Models
Disease-Free Survival
Alkaline Phosphatase
Urine
Neoplasm Metastasis
Survival

Keywords

  • Androgen deprivation therapy
  • Bone turnover
  • Prostate cancer
  • Skeletal-related events

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event. / Hahn, Noah M.; Yiannoutsos, Constantin; Kirkpatrick, Kristina; Sharma, Jaya; Sweeney, Christopher J.

In: Clinical Genitourinary Cancer, Vol. 12, No. 1, 02.2014.

Research output: Contribution to journalArticle

@article{ebb8f12cc7c248d186f9d4958c65e984,
title = "Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event",
abstract = "Background Elevated markers of bone turnover are prognostic for shorter survival in castration-resistant prostate cancer. We aimed to determine the prognostic value of bone turnover markers in metastatic hormone-sensitive prostate cancer. Patients and Methods Markers of bone turnover (urine deoxypyridinoline [DPD] and N-telopeptide, serum bone alkaline phosphatase (AP), and osteocalcin [OC]) from baseline and after 6 months of study were assessed in men enrolled in a prospective metastatic prostate cancer trial with androgen deprivation therapy (ADT) with or without risedronate (ClinicalTrials.gov, NCT00216060). Results Serum samples were collected from 63 patients with bone involvement and a median follow-up of 39.7 months. A multivariate model using Cox regression - which included prostate-specific antigen (PSA) nadir, bisphosphonate treatment, and extent of metastases - showed that suppression of bone turnover markers after 6 months of therapy compared with baseline was significantly associated with longer skeletal-related event (SRE)-free survival. ADT without bisphosphonate therapy was also associated with a decline in markers of bone turnover, presumably resulting from direct anticancer activity. Elevated baseline bone turnover markers were not prognostic. Conclusion Failure to suppress bone turnover while receiving ADT, even when otherwise responding to therapy, may identify patients with hormone-sensitive metastatic prostate cancer who are destined for a shorter time to SREs and progression.",
keywords = "Androgen deprivation therapy, Bone turnover, Prostate cancer, Skeletal-related events",
author = "Hahn, {Noah M.} and Constantin Yiannoutsos and Kristina Kirkpatrick and Jaya Sharma and Sweeney, {Christopher J.}",
year = "2014",
month = "2",
doi = "10.1016/j.clgc.2013.07.002",
language = "English",
volume = "12",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event

AU - Hahn, Noah M.

AU - Yiannoutsos, Constantin

AU - Kirkpatrick, Kristina

AU - Sharma, Jaya

AU - Sweeney, Christopher J.

PY - 2014/2

Y1 - 2014/2

N2 - Background Elevated markers of bone turnover are prognostic for shorter survival in castration-resistant prostate cancer. We aimed to determine the prognostic value of bone turnover markers in metastatic hormone-sensitive prostate cancer. Patients and Methods Markers of bone turnover (urine deoxypyridinoline [DPD] and N-telopeptide, serum bone alkaline phosphatase (AP), and osteocalcin [OC]) from baseline and after 6 months of study were assessed in men enrolled in a prospective metastatic prostate cancer trial with androgen deprivation therapy (ADT) with or without risedronate (ClinicalTrials.gov, NCT00216060). Results Serum samples were collected from 63 patients with bone involvement and a median follow-up of 39.7 months. A multivariate model using Cox regression - which included prostate-specific antigen (PSA) nadir, bisphosphonate treatment, and extent of metastases - showed that suppression of bone turnover markers after 6 months of therapy compared with baseline was significantly associated with longer skeletal-related event (SRE)-free survival. ADT without bisphosphonate therapy was also associated with a decline in markers of bone turnover, presumably resulting from direct anticancer activity. Elevated baseline bone turnover markers were not prognostic. Conclusion Failure to suppress bone turnover while receiving ADT, even when otherwise responding to therapy, may identify patients with hormone-sensitive metastatic prostate cancer who are destined for a shorter time to SREs and progression.

AB - Background Elevated markers of bone turnover are prognostic for shorter survival in castration-resistant prostate cancer. We aimed to determine the prognostic value of bone turnover markers in metastatic hormone-sensitive prostate cancer. Patients and Methods Markers of bone turnover (urine deoxypyridinoline [DPD] and N-telopeptide, serum bone alkaline phosphatase (AP), and osteocalcin [OC]) from baseline and after 6 months of study were assessed in men enrolled in a prospective metastatic prostate cancer trial with androgen deprivation therapy (ADT) with or without risedronate (ClinicalTrials.gov, NCT00216060). Results Serum samples were collected from 63 patients with bone involvement and a median follow-up of 39.7 months. A multivariate model using Cox regression - which included prostate-specific antigen (PSA) nadir, bisphosphonate treatment, and extent of metastases - showed that suppression of bone turnover markers after 6 months of therapy compared with baseline was significantly associated with longer skeletal-related event (SRE)-free survival. ADT without bisphosphonate therapy was also associated with a decline in markers of bone turnover, presumably resulting from direct anticancer activity. Elevated baseline bone turnover markers were not prognostic. Conclusion Failure to suppress bone turnover while receiving ADT, even when otherwise responding to therapy, may identify patients with hormone-sensitive metastatic prostate cancer who are destined for a shorter time to SREs and progression.

KW - Androgen deprivation therapy

KW - Bone turnover

KW - Prostate cancer

KW - Skeletal-related events

UR - http://www.scopus.com/inward/record.url?scp=84892442211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892442211&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.07.002

DO - 10.1016/j.clgc.2013.07.002

M3 - Article

C2 - 24126237

AN - SCOPUS:84892442211

VL - 12

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -